ANATARA LIFESCIENCES LTD competitors & alternatives

Pharmaceuticals

RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.

Pharmaceuticals

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

Veterinary Pharmaceuticals

Parnell Pharmaceuticals Holdings Ltd is a global veterinary pharmaceutical company that develops and manufactures medicines and digital technology platforms for livestock and pets. The company serves veterinarians and animal owners by providing pharmaceutical products for anesthesia, sedation, herd health, and reproductive management, alongside specialized on-farm support services.

Pharmaceuticals

Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.

Pharmaceuticals

Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.

Pharmaceuticals

Guobang Pharma Ltd., a Chinese company, specializes in the research, development, manufacturing, and distribution of pharmaceutical products for both human and veterinary use within China. For human healthcare, their offerings encompass active pharmaceutical ingredients (APIs), intermediate compounds related to these APIs, and finished dosage forms. In the animal health sector, they provide veterinary APIs, various additives, and prepared formulations. The company was founded in 1996 and has its headquarters situated in Xinchang, China.

Life Sciences

ASTRA Therapeutics is a biotechnology and drug design company focused on animal health and anti-parasitic drug discovery. Located at the Swiss Innovation Park Innovaare in Villigen, Switzerland, the company leverages atomic resolution to craft next-generation small-molecule treatments against parasitic diseases.

Life Sciences

Bioniche Life Sciences Inc. was a Canadian biopharmaceutical company focused on developing and commercializing products for human and animal health. It served healthcare providers, patients, livestock producers, veterinarians, and the agricultural industry through pharmaceuticals, vaccines, and related biological products.

BIOMOLECULAR LIFE HOLDINGS, INC.BIOM · BiotechUnited States

62% matchPublic

Biotech

Biomolecular Life Holdings, Inc. develops and commercializes precision nutrition products, luxury-grade nutritional supplements, and wellness technologies. The company serves both human consumers and the companion animal wellness market with science-backed formulations focused on longevity and preventive health.

Kane Biotech Inc.KNE · BiotechWinnipeg, Canada

61% matchPublic

Biotech

Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.

Phoenix Animal Wellness, Inc.BiotechnologyUnited States

60% match

Biotechnology

Phoenix Animal Wellness, Inc. is a biotechnology company that leverages conserved stress-biology pathways to develop solutions for animal health, human therapeutics, and consumer wellness. The company serves the animal and human health sectors through its stress-biology platform.

Axitan Holdings, Inc.BiotechnologyUnited States

60% match

Biotechnology

Axitan Holdings is a biotechnology company that develops novel endolysin-based products to target and neutralize pathogenic bacteria for the animal protein and food safety industries. Its technology provides antibiotic-free solutions to help reduce antimicrobial resistance and address key productivity issues in poultry and livestock production.